Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deutetrabenazine in Tourette Syndrome
NCT03567291Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of deutetrabenazine in Tourette syndrome (TS), sponsored by Teva Pharmaceutical Industries Ltd.. Started May 2018; status: terminated.
02
Drugs
deutetrabenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT03567291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567291.